Tag Archives: C diff patient information

Dale Gerding, MD, FACP, FIDSA, FSHEA To Chair the July 16, 2021 C. diff. Patient, Family, and Caregiver Live-Online Symposium

Scientific Advisor Prof Dale Gerding to chair C. diff. Foundation

C. diff. Patient, Family, and Caregiver Symposium

July 16th  – Live-Online beginning at 1:00 p.m. – 3:00 p.m. EDT 

Register Today!

 

 

 

 

Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, is pleased to announce that its Scientific Advisory Board member, Professor Dale Gerding, a world-leading expert in C. difficile infections (CDI) and the discoverer of NTCD-M3, will be chairing the “C. diff. Patient, Family, and Caregiver” Symposium, to be held virtually on 16 July 2021.

The Symposium, hosted by the C Diff Foundation, will be a gathering of healthcare professionals, practitioners, thought leaders, and C. diff. survivors focused on transforming the patient experience of people living with C. diff. infections worldwide.

Distinguished members and keynote speakers will provide insight on how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.

Destiny Pharma’s late-stage asset, NTCD-M3, is a novel microbiome therapeutic being developed to reduce the recurrence of C. diff. infections in the gut. CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.

NTCD-M3 has the potential to become the leading treatment for CDI, as it has shown to deliver clear advantages to both existing CDI treatment options and also to those currently in clinical development.

About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects. 

Patient Safety With The Centers for Disease Control and Prevention (CDC) Surveillance Antibiotic Resistance Patient Safety Atlas and More

P A T I E N T   S A F E T Y 

CDC’s Antibiotic Resistance Patient Safety Atlas provides open and interactive data about healthcare-associated infections (HAIs) caused by antibiotic resistant bacteria, which are reported to CDC through the National Healthcare Safety Network (NHSN).

You can customize maps and tables to show antibiotic resistance patterns in Healthcare-Associated Infections (HAI’s)  by filtering the data by geographical area (national, regional, and state), time period, event type, and patient age.

For more information visit the following CDC Website:

http://www.cdc.gov/hai/surveillance/ar-patient-safety-atlas.html

Medicaid Covered Outpatient Drugs Policy– Affordable Care Act

On January 21, 2016 the Centers for Medicare & Medicaid Services (CMS) issued the Covered Outpatient Drugs final rule with comment that addresses key areas of Medicaid drug reimbursement and changes made to the Medicaid Drug Rebate Program by the Affordable Care Act. This final rule also requests additional comments on the definition of line extension, which has a 60 day public comment period which will end on April 1, 2016. View the Fact Sheet to learn how this final rule assists states and the federal government in managing drug costs, establishing the long term framework for implementation of the Medicaid drug rebate program, and creating a more fair reimbursement system for Medicaid programs and pharmacies.

 

For additional information regarding Medicaid Covered Outpatient Drugs Policy

click on the link below:

 

https://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/covered-outpatient-drugs-policy.html